Artivion (NYSE:AORT) Delivers Strong Q2 CY2026 Numbers
Artivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and non-GAAP EPS expectations, with full-year revenue guidance around $488M near consensus. The article also highlights margin pressure and YoY EPS decline, suggesting the quality of earnings and operating leverage are key debate points.
Market read
Traders can use the beat versus consensus and the stated full-year revenue outlook to reassess near-term expectations, while monitoring margin efficiency as a potential constraint.
What to watch
Share dilution over the last five years (share count up 24.6%) and the reported margin contraction on a two-year basis may be more important for longer-horizon valuation than the single-quarter beat.
Background
Artivion (formerly CryoLife) makes medical devices and tissue preservation products for cardiac and vascular surgical procedures.
Ticker impact
Artivion reported Q2 CY2026 revenue of $125.8M (+11.3% YoY) and non-GAAP EPS of $0.13, beating Wall Street estimates.
Likely modest positive bias for the next session(s) as traders reprice the beat versus consensus, but follow-through depends on margin trajectory and guidance credibility.
It discloses specific Q2 results versus expectations and reiterates full-year revenue near estimates; however, it also notes margin contraction and EPS down YoY, which can limit upside.
Market effects
Adds incremental datapoints on profitability and operating leverage for medical device companies, but no sector-wide regulatory or demand shock is described.
No specific regional demand, reimbursement, or policy change is cited.
No international expansion, supply chain disruption, or global regulatory action is mentioned.
Counterpoint
Despite the beat, adjusted EPS fell YoY ($0.13 vs $0.24) and operating margin/breakeven efficiency deteriorated, which can cap the stock’s upside.
Key entities
- public_companyArtivion
Medical device company reporting Q2 CY2026 revenue and non-GAAP EPS, plus full-year revenue outlook.
